Short answer
Enliven Therapeutics, Inc. (ELVN) filed an 8-K current report with the SEC on June 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $376.0M net proceeds from sale of 8,933,334 shares at $37.50, strengthening Enliven’s funding position.
Enliven Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $376.0M net proceeds from sale of 8,933,334 shares at $37.50, strengthening Enliven’s funding position
- Additional 1,733,333 pre-funded warrants create near-term dilution potential at $0.001 exercise price
- Underwriters hold a 30-day option for 1,600,000 additional shares, potentially increasing proceeds to $432.4M
- Offering expected to close June 15, 2026, subject to customary conditions
- Capital raise signals substantial financing for corporate or clinical development needs, while increasing share count and dilution risk
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure centers on a planned offering and expected net proceeds
- Offering closing date remains dependent on market conditions and customary closing conditions
- Proceeds could affect liquidity and funding capacity, but timing and amount remain uncertain
- Investors should assess offering risks alongside the Company’s SEC-filed risk factors
Item EX-99.1 · Exhibit EX-99.1
- Upsized offering of 8,933,334 shares and pre-funded warrants for 1,733,333 shares priced at $37.50 per share
- Approximately $400.0 million gross proceeds before underwriting discounts and offering expenses, strengthening clinical-development funding
- Potential additional dilution from underwriters’ 30-day option for 1,600,000 shares
- Closing expected on or about June 15, 2026, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Enliven Therapeutics, Inc. 8-K filings
Get the next ELVN 8-K as it lands
Follow ELVN for push alerts, or ask the research agent what this filing means.